COIOSDeep risk insights through multi-disciplinary research across the globe
grocery store aisle with stocked shelves
Item refines Peer-reviewed Added

First-line SGLT2 inhibitors versus metformin and cardiorenal outcomes in type 2 diabetes

In 36,720 matched pairs, starting SGLT2 inhibitors over metformin was associated with lower risk of major cardiovascular events and death.

This target trial emulation compared adults with type 2 diabetes starting SGLT2 inhibitors or metformin as first-line therapy. Records from a global research network gave 36,720 propensity-matched pairs of new users, 2018 to 2023. SGLT2 inhibitor initiation was associated with lower risk of major adverse cardiovascular events (HR 0.88) and all-cause mortality (HR 0.73). Risks of stroke (HR 0.84), cardiac arrest (HR 0.81) and acute heart failure (HR 0.94) were also lower. Myocardial infarction (HR 0.97) and kidney failure needing replacement therapy (HR 1.00) did not differ. The design is observational, and median follow-up was shorter for SGLT2 inhibitors (2.5 years) than for metformin (3.5 years).

Why it is interesting: The study compares two first-line drugs in type 2 diabetes head to head. SGLT2 inhibitors were linked to fewer deaths, but not to fewer heart attacks or kidney failures.

Source
Mayo Clinic Proceedings, 18 November 2026
Paper
SGLT2 Inhibitors Versus Metformin as First-Line Therapy for Cardiorenal Outcomes: A Target Trial Emulation Among New Users With Type 2 Diabetes
Authors
Kung FP, Tsai CF, Chang YT
DOI
10.1016/j.mayocp.2026.10.024
Type
Peer-reviewed article
Design
Target trial emulation in TriNetX global EHR network, new users 2018-2023 followed to June 2025, 36,720 propensity-matched pairs
Verdict
Refines prior evidence
Driver
Obesity, diabetes and GLP-1
Driver
Innovation in treatment

Other drivers in Health today